NewsBenzingaIambic Therapeutics: BPA del tercer trimestre de $(8,52) frente a una estimación de $(0,72); ventas de $11,351 millones, por debajo de la estimación de $15,133 millones Iambic Therapeutics: BPA del tercer trimestre de $(8,52) frente a una estimación de $(0,72); ventas de $11,351 millones, por debajo de la estimación de $15,133 millones Benzinga 2026.11.16 13:44 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3